Anti-TNF Thioester Glucocorticoid Antibody-Drug Conjugate Fully Inhibits Inflammation with Minimal Effect on Systemic Corticosterone Levels in a Mouse Arthritis Model.
Christopher C MarvinAdrian D HobsonMichael J McPhersonMartin E HayesMeena V PatelDiana L SchmidtTongmei LiJohn T RandolphAgnieszka K BischoffJulia FitzgibbonsLu WangLu WangAxel HernandezYing JiaChristian A GoessShaughn H BryantSuzanne L MathieuJianwen XuPublished in: Journal of medicinal chemistry (2024)
We describe the discovery of a thioester-containing glucocorticoid receptor modulator (GRM) payload and the corresponding antibody-drug conjugate (ADC). Payload 6 was designed for rapid hepatic inactivation to minimize systemic exposure of nonconjugated GRM. Mouse PK indicated that 6 is cleared 10-fold more rapidly than a first-generation GRM payload, resulting in 10-fold lower exposure and 3-fold decrease in Cmax. The anti-mTNF conjugate ADC5 fully inhibited inflammation in mouse contact hypersensitivity with minimal effects on corticosterone, a biomarker for systemic GRM effects, at doses up to and including 100 mg/kg. Concomitant inhibition of P1NP suggests potential delivery to cells involved in the remodeling of bone, which may be a consequence of TNF-targeting or bystander payload effects. Furthermore, ADC5 fully suppressed inflammation in collagen-induced arthritis mouse model after one 10 mg/kg dose for 21 days. The properties of the anti-hTNF conjugate were suitable for liquid formulation and may enable subcutaneous dosing.
Keyphrases
- rheumatoid arthritis
- cancer therapy
- oxidative stress
- mouse model
- drug induced
- induced apoptosis
- drug delivery
- diffusion weighted
- small molecule
- computed tomography
- high throughput
- bone mineral density
- high glucose
- cell cycle arrest
- climate change
- ionic liquid
- cell proliferation
- risk assessment
- magnetic resonance
- body composition
- bone loss